OPKO Health (OPK) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
OPKO Announces Second Quarter Operating and Financial Results
August 5, 2015 4:00 PM EDTAnnounced the Acquisition of Bio-Reference Laboratories; Closing Anticipated by the End of August Acquired EirGen Pharma, A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer RayaldeeTM New Drug Application (NDA) Submission Accepted by FDA; Expected PDUFA date of March 29, 2016 Completed the Enrollment in hGH-CTP Phase 3 Trial in Growth Hormone Deficient Adults New Pre-Clinical Data Supporting Subcutaneous Administration for Long Acting Factor VIIa-CTP for Hemophilia; Phase 2a Clinical Trial Expected to Commence in Q3 2015... More
